
Harald Hegen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3752243/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. Journal of Neuroinflammation, 2022, 19, 19.	3.1	82
2	Comparing humoral immune response to SARSâ€CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study. European Journal of Neurology, 2022, 29, 1538-1544.	1.7	12
3	Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate. Wiener Medizinische Wochenschrift, 2022, , 1.	0.5	2
4	Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis—from diagnosis to prediction of disease activity. Wiener Medizinische Wochenschrift, 2022, 172, 337-345.	0.5	9
5	Effects of actual and imagined music-cued gait training on motor functioning and brain activity in people with multiple sclerosis: protocol of a randomised parallel multicentre trial. BMJ Open, 2022, 12, e056666.	0.8	1
6	Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis. Journal of Central Nervous System Disease, 2022, 14, 117957352210848.	0.7	0
7	Olfactory threshold predicts treatment response in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1541-1552.	1.4	3
8	Caspr2 antibodies in herpes simplex encephalitis: an extension of the spectrum of virus induced autoimmunity? – A case report. BMC Neurology, 2022, 22, 131.	0.8	2
9	Alemtuzumab induced hemodynamic change in relapsing multiple sclerosis occurs independent of corticosteroid premedication – a retrospective multicentre study. Multiple Sclerosis and Related Disorders, 2022, 63, 103810.	0.9	4
10	German guideline for diagnosis and treatment of multiple sclerosis – a survey focusing neurologists in daily practise. Multiple Sclerosis and Related Disorders, 2022, 63, 103828.	0.9	1
11	Sudomotor dysfunction in people with neuromyelitis optica spectrum disorders. European Journal of Neurology, 2022, 29, 2772-2780.	1.7	3
12	Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1871-1880.	1.4	5
13	Longâ€ŧerm outcome after <scp>COVID</scp> â€19 infection in multiple sclerosis: A nationâ€wide multicenter matchedâ€control study. European Journal of Neurology, 2022, 29, 3050-3060.	1.7	9
14	Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study. Multiple Sclerosis and Related Disorders, 2022, 65, 104009.	0.9	3
15	Multiple sclerosis and COVIDâ€19: How many are at risk?. European Journal of Neurology, 2021, 28, 3369-3374.	1.7	37
16	Macular ganglion cell–inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 684-694.	1.4	36
17	Cerebrospinal fluid protein in Guillain–Barré syndrome: Need for ageâ€dependent interpretation. European Journal of Neurology, 2021, 28, 965-973.	1.7	12
18	Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score. European Journal of Neurology, 2021, 28, 1609-1616.	1.7	18

#	Article	IF	CITATIONS
19	Oligoclonal Bands: Isoelectric Focusing and Immunoblotting, and Determination of \hat{I}^2 Free Light Chains in the Cerebrospinal Fluid. Neuromethods, 2021, , 29-54.	0.2	0
20	Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis. European Journal of Neurology, 2021, 28, 2037-2045.	1.7	10
21	Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	26
22	Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study. Frontiers in Immunology, 2021, 12, 641106.	2.2	2
23	Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	16
24	Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study. Frontiers in Immunology, 2021, 12, 675307.	2.2	12
25	COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry. PLoS ONE, 2021, 16, e0255316.	1.1	27
26	Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study. Multiple Sclerosis Journal, 2021, 27, 2209-2218.	1.4	25
27	SARS-CoV2 infection as a potential trigger for severe relapse in a patient with multiple sclerosis who stopped disease modifying treatment due to COVID-19 pandemic. Neuroimmunology Reports, 2021, 1, 100005.	0.2	Ο
28	Muscle involvement in SARS oVâ€⊋ infection. European Journal of Neurology, 2021, 28, 3411-3417.	1.7	40
29	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Varicella Zoster Virus Infection - Frequency of an Association. Frontiers in Immunology, 2021, 12, 769653.	2.2	3
30	Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15Âyears. Scientific Reports, 2021, 11, 23317.	1.6	4
31	Implementation study of the 2021 German guideline for diagnosis and treatment of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 57, 103434.	0.9	2
32	Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPRiMS Score. Frontiers in Neurology, 2021, 12, 766956.	1.1	5
33	Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration. Multiple Sclerosis Journal, 2020, 26, 57-68.	1.4	20
34	Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria. Multiple Sclerosis Journal, 2020, 26, 69-78.	1.4	51
35	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Multiple Sclerosis Journal, 2020, 26, 912-923.	1.4	52
36	Impairment of odor discrimination and identification is associated with disability progression and gray matter atrophy of the olfactory system in MS. Multiple Sclerosis Journal, 2020, 26, 706-715.	1.4	14

#	Article	IF	CITATIONS
37	Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1682-1690.	1.4	25
38	To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis and Related Disorders, 2020, 39, 101908.	0.9	29
39	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. Frontiers in Neurology, 2020, 11, 579438.	1.1	9
40	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. PLoS ONE, 2020, 15, e0239453.	1.1	7
41	Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732094573.	0.5	2
42	Transverse myelitis as a rare presentation of antiphospholipid-antibody-associated disorders. Multiple Sclerosis and Related Disorders, 2020, 45, 102405.	0.9	0
43	Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732096634.	0.5	15
44	Validation of inter-eye difference thresholds in optical coherence tomography for identification of optic neuritis in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102403.	0.9	22
45	Recent developments in MOG-IgG associated neurological disorders. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642094513.	1.5	45
46	Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS. BMC Medicine, 2020, 18, 298.	2.3	11
47	Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab. Multiple Sclerosis and Related Disorders, 2020, 43, 102155.	0.9	18
48	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. PLoS ONE, 2020, 15, e0234333.	1.1	2
49	Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases. Frontiers in Immunology, 2020, 11, 1188.	2.2	16
50	International multicenter examination of MOG antibody assays. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	180
51	Commentary to "Letter to the editor: To treat or not to treat study - Comparative group inclusion considerations―for multiple sclerosis and related disorders. Multiple Sclerosis and Related Disorders, 2020, 40, 101975.	0.9	0
52	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
53	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
54	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0

Harald Hegen

#	Article	IF	CITATIONS
55	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
56	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
57	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. , 2020, 15, e0234333.		0
58	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0
59	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0
60	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0
61	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. , 2020, 15, e0239453.		0
62	A Survey of Cerebrospinal Fluid Total Protein Upper Limits in Canada: Time for an Update?. Canadian Journal of Neurological Sciences, 2019, 46, 283-286.	0.3	2
63	Conversion and reversion of antiâ€John Cunningham virus antibody serostatus: A prospective study. Brain and Behavior, 2019, 9, e01332.	1.0	7
64	Free light chains in the cerebrospinal fluid. Comparison of different methods to determine intrathecal synthesis. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1574-1586.	1.4	25
65	Dataset for worldwide survey of cerebrospinal total protein upper reference values. Data in Brief, 2019, 23, 103760.	0.5	0
66	The clinical significance of single or double bands in cerebrospinal fluid isoelectric focusing. A retrospective study and systematic review. PLoS ONE, 2019, 14, e0215410.	1.1	23
67	Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731988598.	0.5	6
68	Admission diagnoses of patients later diagnosed with autoimmune encephalitis. Journal of Neurology, 2019, 266, 124-132.	1.8	34
69	Adult CSF total protein: Higher upper reference limits should be considered worldwide. A web-based survey. Journal of the Neurological Sciences, 2019, 396, 48-51.	0.3	20
70	Peripapillary retinal nerve fibre layer thinning rate as a biomarker discriminating stable and progressing relapsing–remitting multiple sclerosis. European Journal of Neurology, 2019, 26, 865-871.	1.7	32
71	Adult CSF total protein upper reference limits should be age-partitioned and significantly higher than 0.45Âg/L: a systematic review. Journal of Neurology, 2019, 266, 616-624.	1.8	41
72	Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 196-203.	1.4	67

#	Article	IF	CITATIONS
73	Change of olfactory function as a marker of inflammatory activity and disability progression in MS. Multiple Sclerosis Journal, 2019, 25, 267-274.	1.4	29
74	â€~No evidence of disease activity' – is it an appropriate surrogate in multiple sclerosis?. European Journal of Neurology, 2018, 25, 1107.	1.7	55
75	Cerebrospinal fluid free light chains as diagnostic biomarker in neuroborreliosis. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1383-1391.	1.4	21
76	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain, 2018, 141, 1085-1093.	3.7	115
77	Smoking is not associated with higher prevalence of JC virus in MS patients. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 907-910.	1.3	2
78	Vascular diseases and bleedings. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 207-236.	1.0	3
79	Cerebrospinal fluid:serum glucose ratio in the ventricular and lumbar compartments: implications for clinical practice. European Journal of Neurology, 2018, 25, 373-379.	1.7	12
80	Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis. Frontiers in Immunology, 2018, 9, 2435.	2.2	1
81	Autoantibodies against neuronal surface proteins in spontaneous subarachnoid and intracerebral haemorrhage. BMC Neurology, 2018, 18, 89.	0.8	0
82	Transient impairment of olfactory threshold in acute multiple sclerosis relapse. Multiple Sclerosis and Related Disorders, 2018, 23, 74-77.	0.9	19
83	Utility of Two-Dimensional Difference Gel Electrophoresis in Diagnosis of Multiple Sclerosis. Diagnostics, 2018, 8, 44.	1.3	1
84	Persistency of Neutralizing Anti-Interferon-β Antibodies in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon-β Depends on Antibody Titers, IgG Subclasses, and Affinity Maturation. Journal of Interferon and Cytokine Research, 2017, 37, 317-324.	0.5	5
85	Combined evaluation of personality, risk and coping in MS patients: A step towards individualized treatment choice – The PeRiCoMS-Study I. Journal of the Neurological Sciences, 2017, 376, 71-75.	0.3	7
86	Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors. Multiple Sclerosis Journal, 2017, 23, 1241-1248.	1.4	56
87	Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study. PLoS ONE, 2017, 12, e0182462.	1.1	26
88	Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study. PLoS ONE, 2017, 12, e0174005.	1.1	29
89	Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis—The PaSiMS II study. PLoS ONE, 2017, 12, e0181458.	1.1	2
90	Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study. PLoS ONE, 2016, 11, e0158978.	1.1	56

#	Article	IF	CITATIONS
91	Quantitation of intrathecal immunoglobulin synthesis – a new empirical formula. European Journal of Neurology, 2016, 23, 713-721.	1.7	28
92	Serum Cotinine Does Not Predict Neutralizing Antibodies Against Interferon Beta in an Austrian MS Cohort. Journal of Interferon and Cytokine Research, 2016, 36, 667-670.	0.5	5
93	Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients. Drugs, 2016, 76, 1421-1445.	4.9	14
94	Bi-insular cortical involvement in anti-NMDA-receptor encephalitis – a case report. BMC Neurology, 2016, 16, 130.	0.8	12
95	Rethinking the importance of paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis: They do matter. Multiple Sclerosis and Related Disorders, 2016, 9, 150-154.	0.9	11
96	A6.12â€Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases. Annals of the Rheumatic Diseases, 2016, 75, A52.1-A52.	0.5	0
97	Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases. Arthritis Research and Therapy, 2016, 18, 49.	1.6	32
98	Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e202.	3.1	34
99	Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study. Multiple Sclerosis Journal, 2016, 22, 502-510.	1.4	87
100	Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity. Clinical Chemistry and Laboratory Medicine, 2016, 54, 285-92.	1.4	67
101	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
102	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	3.7	147
103	Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1803-1819.	1.5	22
104	Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial. Journal of Neuroimmunology, 2015, 287, 98-105.	1.1	8
105	Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Multiple Sclerosis Journal, 2014, 20, 577-587.	1.4	40
106	Serum glucose adjusted cut-off values for normal cerebrospinal fluid/serum glucose ratio: implications for clinical practice. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1335-40.	1.4	20
107	High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) – A pilot study. Multiple Sclerosis and Related Disorders, 2014, 3, 220-226.	0.9	3
108	Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Multiple Sclerosis Journal, 2013, 19, 1533-1538.	1.4	92

#	Article	IF	CITATIONS
109	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1802-1809.	1.4	133
110	Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Multiple Sclerosis Journal, 2012, 18, 610-615.	1.4	31
111	Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. Journal of Neuroinflammation, 2011, 8, 184.	3.1	379
112	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. Laboratoriums Medizin, 2010, 34, 1-12.	0.1	3
113	Endothelin and nitric oxide as cerebrospinal fluid biomarkers for cerebral vasospasm following subarachnoid haemorrhage / Endothelin und NO als Liquorbiomarker für cerebralen Vasospasmus nach Subarachnoidalblutung. Laboratoriums Medizin, 2010, 34, 343-347.	0.1	Ο
114	Cerebrospinal fluid biomarkers in bacterial meningitis / Biomarker im Liquor cerebrospinalis bei bakterieller Meningitis. Laboratoriums Medizin, 2009, 33, 321-331.	0.1	3